Nemaura Medical (OTCMKTS:NMRD – Get Free Report) is expected to announce its resultson Wednesday, June 3rd. Analysts expect the company to announce earnings of ($0.08) per share for the quarter.
Nemaura Medical Stock Performance
Nemaura Medical has a twelve month low of $0.00 and a twelve month high of $0.05.
Nemaura Medical Company Profile
Nemaura Medical PLC is a medical technology company focused on developing non‐invasive monitoring solutions for diabetes management and other metabolic applications. The company’s core offering centers on sugarBEAT, a wearable continuous glucose monitoring (CGM) system designed to provide real-time glucose readings through a disposable skin patch. By eliminating the need for finger-stick testing, Nemaura aims to improve patient comfort and adherence, particularly for individuals managing type 1 and type 2 diabetes.
The sugarBEAT system utilizes a proprietary, mild electric current to extract interstitial fluid through micro-pores in the skin, enabling glucose measurement without needle penetration.
Further Reading
- Five stocks we like better than Nemaura Medical
- Banks Are Buying Back Stock Hand Over Fist, Including These 3 Names
- 2 Aluminum Stocks Poised for Big Tariff-Related Gains
- AutoZone’s Pullback Sets Up a Long-Term Buying Opportunity
- AST SpaceMobile’s June Launch Plan Puts Its 2026 Satellite Goal Back in Focus
Receive News & Ratings for Nemaura Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nemaura Medical and related companies with MarketBeat.com's FREE daily email newsletter.
